News Biofrontera mulls US IPO to fund skin cancer drug German biotech Biofrontera is considering a US stock market listing to fund development and marketing of a skin cancer drug.
News FDA greenlights Regeneron drug for rare bone disease Regeneron's Pasatru will be the second FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
